Pune: The Serum Institute of India (SII) is gearing up to launch another COVID-19 vaccine – Covovax, which is developed in partnership with America’s Novavax.
CEO Adar Poonawalla is hopeful of launching the vaccine by Septembe
r this year. He notified that the vaccine has been tested against UK and African variants of the virus and has an efficacy of 89 per cent.
SII is conducting phase 2 and 3 bridging study of 1,600 participants for this vaccine.
This COVID-19 vaccine will be SII’s second in India. It is already supplying Covishield – made by Oxford University in collaboration with AstraZeneca.
There is speculation that the Russian vaccine Sputnik V which is currently being made by five firms in India, will be the next vaccine to be approved here. It has an efficacy of 91.6 per cent.
Also Read: COVID-19: Sputnik V To Be Made By 5 Firms In India